Drug-resistant Gram-negative bacterial infections are increasing at an alarming rate and treatment options for these types of infections are still a challenge in the modern world. Complicated urinary tract infections, complicated intra-abdominal infections, hospital-acquired pneumonia (including ventilator-acquired pneumonia), sepsis, and skin and soft tissue infections are the most commonly encountered gram-negative infections. Over the last decade, an increase in carbapenem-resistant isolates has resulted in the widespread use of colistin as a __ampersandsignlsquo;last resort__ampersandsignrsquo; of antimicrobial agents. However, an increase in colistin resistance is a major concern that leads to the spectre of untreatable Gram-negative infections with difficult antibiotic therapy. To overcome the resistance against gram-negative bacterial infections, an agent called ceftazidime-avibactam was introduced. The drug is mainly active against multi-resistant gram-negative organisms such as Enterobacteriaceae (E.coli, Klebsiella pneumonia ) and Pseudomonas aeruginosa, including those expressing certain types of Class A, Class C, and Class D enzymes. Dosage regimen for ceftazidime-avibactam can be expressed as total grams of combination product and its typical dosing is 2.5g administered every 8 hours by intravenous infusion over 2 hours in adults. It is a well-tolerated drug with no nephrotoxicity compared to colistin. Dose adjustment is needed according to the variation in creatinine clearance of the patient.